Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALAD | P13716 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8935127 | 0.98 | DAO (0.95) | DAOGSK3BGPR35ALDH1A1KDM4E | |
| SCHEMBL7040416 | 0.82 | DAO (0.69) | DAOGSK3BGPR35ALDH1A1MEN1 | |
| SCHEMBL8935123 | 0.81 | DAO (0.68) | DAOGSK3BALDH1A1MEN1MAPT | |
| SCHEMBL18701535 | 0.79 | DAO (0.65) | DAOGSK3BGPR35ALDH1A1KDM4E | |
| SCHEMBL2987123 | 0.79 | DAO (0.65) | DAOGSK3BMAPT | |
| SCHEMBL18701713 | 0.79 | DAO (0.65) | DAOGSK3BGPR35ALDH1A1KDM4E | |
| SCHEMBL5009880 | 0.79 | DAO (0.65) | DAOGSK3BALDH1A1KDM4EMAPT | |
| SCHEMBL7816128 | 0.77 | DAO (0.63) | DAOGSK3BGPR35ALDH1A1KDM4E | |
| SCHEMBL1530004 | 0.77 | DAO (0.63) | DAOGSK3BGPR35ALDH1A1KDM4E | |
| SCHEMBL18701697 | 0.77 | DAO (0.63) | DAOGSK3BGPR35ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218878-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2022-07-14 | — | — | US | claimed |
| CN-110118836-B | Method for determining genotoxic impurities in rivaroxaban by high performance liquid chromatography | 北京悦康科创医药科技股份有限公司 | 2021-10-29 | — | — | CN | claimed |
| WO-2020243047-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2020-12-03 | — | — | WO | claimed |
| CN-110118836-A | The method of genetoxic impurity in high effective liquid chromatography for measuring razaxaban | 北京悦康科创医药科技股份有限公司 | 2019-08-13 | — | — | CN | claimed |
| EP-2616466-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | Medichem, S.A. (ES) | 2013-07-24 | — | — | EP | claimed |
| WO-2012035057-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | MEDICHEM S.A. (ES) | 2012-03-22 | — | — | WO | claimed |
| US-6010714-A | BLEND CONTAINING HEAT DISSIPATING AGENT | CLOSURE MEDICAL CORPORATION (US) | 2000-01-04 | — | — | US | claimed |
| CN-115433173-B | Quinoxaline derivative, preparation and application thereof | 上海交通大学 | 2025-04-01 | — | — | CN | disclosed |
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-01-02 | — | — | US | disclosed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| US-6010714-A | BLEND CONTAINING HEAT DISSIPATING AGENT | CLOSURE MEDICAL CORPORATION (US) | 2000-01-04 | — | — | US | disclosed |
| US-5840917-A | ADMINISTERING TO MAMMAL TO ERADICATE HELICOBACTER PYLORI | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998042347-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A PHOSPHORYLAMIDE AND AN AYNTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-01 | — | — | WO | disclosed |
| EP-0852498-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997011705-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | DAO 449/4885GSK3B 789/4885GPR35 2376/4885 |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | DAO 449/4885GSK3B 789/4885GPR35 2376/4885 |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORT1, GRN, SCARB1 | DAO 3871/4885GSK3B 2603/4885GPR35 779/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | DAO 449/4885GSK3B 789/4885GPR35 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.